Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency and modernization, including through the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs. Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24. Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023). Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy. Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the life sciences and biopharmaceutical sectors. Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Communicating with government officials about regulations, guidelines, reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB"). Communicating with government officials about regulations related to patented medicines, including the "Patented Medicines (Notice of Compliance) Regulations" (SOR/93-133) under the Patent Act. Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments. Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products. Communicating with government officials about federal healthcare plans and benefits. Communicating with government officials about the Government of Canada's "Biomanufacturing and Life Sciences Strategy" (2021). Communicating with government officials about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health). Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.